[Research progress in the study of brain microdialysis in glioma]
Abstract:
Glioma is the most common form of brain cancer. Despite recent advances in the treatment of solid tumors, there are few effective treatments for malignant gliomas due to its infiltrative nature. It has important significance to improve the treatment of glioma through in-depth understanding the intracerebral metabolic characteristics and pharmacokinetics of chemotherapeutics. Brain microdialysis (B-MD), an effective method to monitor central nervous system anticancer drug disposition, conditions of drugs through the blood-brain barrier, basic pathophysiologic metabolism, bioactive compounds and the changes of neurotransmitter in brain, provides the unique opportunity to allow the simultaneous determination of unbound concentrations of drugs in several tissues, and directly measure gliomas biochemistry continuously. B-MD has been able to monitor the change of brain drugs, metabolites and neurotransmitters, dynamic analysis of the drug concentration and pharmacological effect after administration, pharmacodynamic interaction between drugs, receptor mechanism of drug transport, as well as feedback information of internal environment. B-MD is expected to provide reference for clinical individual chemotherapy of glioma, but also provide powerful tools for the evaluation of new anticancer drugs in vivo. In this review, a comprehensive overview of B-MD for studies on glioma is elucidated with special emphasis on its application to neurochemistry and pharmacokinetic studies.
Insights
Brain microdialysis (B-MD) offers a novel approach to understanding glioma, the most common brain cancer. This method enables continuous monitoring of intracerebral drug concentrations and brain biochemistry, aiding in personalized chemotherapy and new drug evaluation.
Area of Science:
- Neuroscience
- Oncology
- Pharmacology
Background:
- Glioma, a prevalent brain cancer, presents treatment challenges due to its infiltrative nature.
- Understanding intracerebral metabolic characteristics and drug pharmacokinetics is crucial for improving glioma treatment.
- Current treatments for malignant gliomas remain limited, highlighting the need for innovative therapeutic strategies.
Purpose of the Study:
- To provide a comprehensive overview of brain microdialysis (B-MD) applications in glioma research.
- To emphasize the utility of B-MD in neurochemistry and pharmacokinetic studies relevant to glioma.
- To explore how B-MD can inform personalized chemotherapy and evaluate novel anticancer drugs for glioma.
Main Methods:
- Brain microdialysis (B-MD) is presented as an effective method for monitoring the central nervous system.
- B-MD allows for simultaneous determination of unbound drug concentrations in various brain tissues.
- This technique enables continuous measurement of glioma biochemistry and monitoring of neurotransmitter changes.
Main Results:
- B-MD facilitates continuous monitoring of drug disposition across the blood-brain barrier.
- The method allows for dynamic analysis of drug concentration, pharmacological effects, and interactions.
- B-MD provides insights into brain metabolism, bioactive compounds, and neurotransmitter alterations in the context of glioma.
Conclusions:
- Brain microdialysis is a valuable tool for advancing glioma research and treatment.
- B-MD offers unique opportunities for in-depth analysis of intracerebral pharmacokinetics and neurochemistry in glioma.
- The application of B-MD is expected to guide individualized glioma chemotherapy and facilitate the evaluation of new anticancer drugs.
